Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
Total Valuation
Aptevo Therapeutics has a market cap or net worth of $4.93M. The enterprise value is -$9.57M.
Market Cap$4.93M
Enterprise Value-$9.57M
Share Statistics
Aptevo Therapeutics has 1,181,725 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,181,725
Owned by Insiders1.15%
Owned by Institutions<0.01%
Financial Efficiency
Aptevo Therapeutics’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -119.55%.
Return on Equity (ROE)-1.49
Return on Assets (ROA)-0.95
Return on Invested Capital (ROIC)-119.55%
Return on Capital Employed (ROCE)-1.24
Revenue Per Employee0.00
Profits Per Employee-701.81K
Employee Count37
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aptevo Therapeutics is ―. Aptevo Therapeutics’s PEG ratio is 0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio0.00001
Income Statement
In the last 12 months, Aptevo Therapeutics had revenue of 0.00 and earned -25.97M in profits. Earnings per share was -87.27.
Revenue0.00
Gross Profit-240.00K
Operating Income-26.31M
Pretax Income-25.97M
Net Income-25.97M
EBITDA-26.07M
Earnings Per Share (EPS)-87.27
Cash Flow
In the last 12 months, operating cash flow was -25.59M and capital expenditures 0.00, giving a free cash flow of -25.59M billion.
Operating Cash Flow-25.59M
Free Cash Flow-25.59M
Free Cash Flow per Share-21.66
Dividends & Yields
Aptevo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.04
52-Week Price Change-98.85%
50-Day Moving Average6.15
200-Day Moving Average25.42
Relative Strength Index (RSI)33.83
Average Volume (3m)11.64M
Important Dates
Aptevo Therapeutics upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Aptevo Therapeutics as a current ratio of 3.82, with Debt / Equity ratio of 26.63%
Current Ratio3.82
Quick Ratio3.82
Debt to Market Cap16.59
Net Debt to EBITDA0.65
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aptevo Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aptevo Therapeutics EV to EBITDA ratio is 0.65, with an EV/FCF ratio of 0.66.
EV to Sales0.00
EV to EBITDA0.65
EV to Free Cash Flow0.66
EV to Operating Cash Flow0.66
Balance Sheet
Aptevo Therapeutics has $21.62M in cash and marketable securities with $4.63M in debt, giving a net cash position of $16.99M billion.
Cash & Marketable Securities$21.62M
Total Debt$4.63M
Net Cash$16.99M
Net Cash Per Share$14.38
Tangible Book Value Per Share$5.51K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aptevo Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.00
Price Target Upside3342.62% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast99.02%